Mesh Stents Study in ILIAC Complex Lesions (IMS-Study) (IMS)
Primary Purpose
Peripheral Arterial Disease, Iliac Artery Stenosis, Embolus Arterial
Status
Not yet recruiting
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Iliac Stenting
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Arterial Disease focused on measuring Iliac artery stenosis, High-risk plague, Mesh stent, Peripheral embolisation, Peripheral arterial disease
Eligibility Criteria
Inclusion Criteria:
General Inclusion Criteria (principal):
- Patients older than 18 years, after Vascular Team evaluation, according to local standards, eligible for Iliac artery
- Written, informed consent to participate
- Agreement to attend Protocol required (standard) follow up visits and examinations
Angiographic Inclusion Criteria (principal):
- De novo iliac stenosis
- Stenosis eligible for endovascular treatment per Vascular Team evaluation (according to current standards and guidelines)
- High-risk morphology stenosis with complex/thrombotic lesions (per 1 independent, experienced operator).
Exclusion Criteria:
General Exclusion Criteria (principal):
- Life expectancy <1 year (e.g., active neoplastic disease).
- Chronic kidney disease with creatinine > 3.0 mg/dL.
- Coagulopathy.
- Contraindication for decoagulation
- History of uncontrolled contrast media intolerance
- Myocardial infarction in 72 hours preceding the stenting procedure (if possible, postponing the procedure)
- Stroke in 6 weeks preceding the stenting procedure (if possible, postponing the procedure)
- Pregnancy (positive pregnancy test)
AngiographicExclusion Criteria (principal):
- Chronic total occlusion not amenable to re-canalization
- Stent in the target vessel/lesion
- Anatomic variants precluding stent implantation
- Mobile (free-floating) plaque elements in aorta or arteries proximal to the target lesion
Sites / Locations
- Medical Universtity of Warsaw
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Conventional Implantation of mesh stent
Arm Description
Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
Outcomes
Primary Outcome Measures
MACNE (Major Adverse Cardiac or Neurological Event )
In-hospital MACNE (death, stroke, myocardial infarction, acute limb or target organ ischemia)
Secondary Outcome Measures
Full Information
NCT ID
NCT05377775
First Posted
April 29, 2022
Last Updated
May 16, 2022
Sponsor
Medical University of Warsaw
1. Study Identification
Unique Protocol Identification Number
NCT05377775
Brief Title
Mesh Stents Study in ILIAC Complex Lesions (IMS-Study)
Acronym
IMS
Official Title
Mesh Stents Study in Iliac Complex Lesions Iliac-Mesh Stent Study (IMS-Study)
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 10, 2022 (Anticipated)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Warsaw
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main objective of the IMS-Study is to evaluate the short and long-term safety and efficacy of mesh stent implantation in patients with stenotic iliac disease with complex plaques or lesions containing thrombotic material.
Detailed Description
Iliac artery disease may include complex lesions with a vulnerable plaque and containing thrombotic materials. The treatment of these complex plaques is frequently complicated with local, acute occlusion, dissection and distal embolisation.
Studies with a mesh stent in the carotid region have shown a reduced risk of peripheral embolization. The use of mesh stents in iliac arteries can provide similar benefits. The structure of the stents, sizes, and the release system do not require any changes. The study is to assess the usefulness of mesh stents in preventing peripheral embolisation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease, Iliac Artery Stenosis, Embolus Arterial, Ischemic Leg
Keywords
Iliac artery stenosis, High-risk plague, Mesh stent, Peripheral embolisation, Peripheral arterial disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective, single-center, open-label, single-arm, non-randomized clinical trial.
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Conventional Implantation of mesh stent
Arm Type
Experimental
Arm Description
Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
Intervention Type
Device
Intervention Name(s)
Iliac Stenting
Intervention Description
Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
Primary Outcome Measure Information:
Title
MACNE (Major Adverse Cardiac or Neurological Event )
Description
In-hospital MACNE (death, stroke, myocardial infarction, acute limb or target organ ischemia)
Time Frame
48 hours after procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
General Inclusion Criteria (principal):
Patients older than 18 years, after Vascular Team evaluation, according to local standards, eligible for Iliac artery
Written, informed consent to participate
Agreement to attend Protocol required (standard) follow up visits and examinations
Angiographic Inclusion Criteria (principal):
De novo iliac stenosis
Stenosis eligible for endovascular treatment per Vascular Team evaluation (according to current standards and guidelines)
High-risk morphology stenosis with complex/thrombotic lesions (per 1 independent, experienced operator).
Exclusion Criteria:
General Exclusion Criteria (principal):
Life expectancy <1 year (e.g., active neoplastic disease).
Chronic kidney disease with creatinine > 3.0 mg/dL.
Coagulopathy.
Contraindication for decoagulation
History of uncontrolled contrast media intolerance
Myocardial infarction in 72 hours preceding the stenting procedure (if possible, postponing the procedure)
Stroke in 6 weeks preceding the stenting procedure (if possible, postponing the procedure)
Pregnancy (positive pregnancy test)
AngiographicExclusion Criteria (principal):
Chronic total occlusion not amenable to re-canalization
Stent in the target vessel/lesion
Anatomic variants precluding stent implantation
Mobile (free-floating) plaque elements in aorta or arteries proximal to the target lesion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Piotr Myrcha, MD, PhD
Phone
+48 607 366 683
Email
piotrmyr@poczta.fm
First Name & Middle Initial & Last Name or Official Title & Degree
Izabela Taranta, PhD
Phone
0048508190957
Email
iza.taranta@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Piotr Myrcha, Ass.Prof.
Organizational Affiliation
Medical University of Warsaw
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Universtity of Warsaw
City
Warsaw
State/Province
Mazowieckie
ZIP/Postal Code
03-242
Country
Poland
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
https://pubmed.ncbi.nlm.nih.gov/30266356/
Description
Randomized trial comparing CGuard™ stent vs. Wallstent™
URL
https://pubmed.ncbi.nlm.nih.gov/33855877/
Description
Thirty-Day Results of the Novel CGuard-Covered Stent in Patients Undergoing Carotid Artery Stenting
URL
https://pubmed.ncbi.nlm.nih.gov/31060430/
Description
CGuard MicroNet-Covered "One-Size-Fits-All" Carotid Stent
URL
https://pubmed.ncbi.nlm.nih.gov/34391704/
Description
The IRONGUARD 2 Study
URL
https://pubmed.ncbi.nlm.nih.gov/30945420/
Description
Analysis from the PARADIGM study
Learn more about this trial
Mesh Stents Study in ILIAC Complex Lesions (IMS-Study)
We'll reach out to this number within 24 hrs